PharmaTher Holdings Ltd (PHRRF)
OTHER OTC:PHRRF
PHRRF Stock Chart & Stats
$0.08
>-$0.01(-1.68%)
At close: 4:00 PM EST
$0.08
>-$0.01(-1.68%)
Day’s Range― - ―
52-Week Range$0.04 - $0.55
Previous CloseN/A
Volume116.52K
Average Volume (3M)657.06K
Market Cap
$4.29M
Enterprise Value$5.21M
Total Cash (Recent Filing)$1.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume787,919
30 Day Avg. Volume657,056
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)16.46
Price to Sales (P/S)0.00
P/FCF Ratio-13.24
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing Losses & Improved BurnMaterially narrowing net losses and an improved cash burn trajectory indicate stronger cost discipline and operational efficiency. Over 2-6 months this improves runway, reduces near-term funding pressure and dilution risk, and shows management can slow cash outflows while R&D continues.
Zero Reported DebtA debt-free balance sheet lowers fixed financing obligations and financial distress risk, giving the company structural flexibility to prioritize R&D and clinical programs. This durable capital structure advantage eases near-term liquidity management and preserves optionality for strategic financing.
Focused IP In Psychedelic TherapeuticsA concentrated portfolio of ketamine-based and psychedelic-inspired therapeutics plus delivery IP targets a growing, structurally supportive mental-health sector. Durable competitive advantages from proprietary formulations and delivery methods could enable differentiated products and multiple commercialization pathways.
Bears Say
Pre-revenue Business ModelOperating with no commercial revenue leaves the business entirely dependent on R&D progress and external financing. Over the next several months this structural lack of cash inflow heightens execution risk, ties viability to clinical milestones, and limits self-funded growth options.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow, despite improvement versus prior periods, implies continued reliance on outside capital. This structural cash burn pattern raises the probability of future equity financings, potential dilution, and constrained ability to scale programs without securing additional funding.
Eroding Equity CushionA sharply reduced equity base weakens the company’s shock absorbers against further losses and increases insolvency risk if cash burn continues. Over months this structural erosion can limit financing options, push higher-cost capital and pressure strategic flexibility for clinical development.
PharmaTher Holdings Ltd News
PHRRF FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was $0.04 and its highest was $0.55 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is $4.29M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Sep 24, 2026 which is in 162 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
PharmaTher Holdings Ltd released its earnings results on Jan 30, 2026. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd does not currently pay dividends.
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 91,019,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
PharmaTher Holdings Ltd reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in PHRRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
BetterLife Pharma
―
BioVaxys Technology
―
Marvel Biosciences Corp
―
Ownership Overview
19.68% Insiders
<0.01% Other Institutional Investors
80.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---